Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs1 1The Institute for Effectiveness Research, LLC, is a subsidiary of Medco Health Solutions, Inc., a Merck Company.
- 1 August 2003
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 125 (2) , 389-395
- https://doi.org/10.1016/s0016-5085(03)00900-4
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Serious lower gastrointestinal clinical events with nonselective NSAID or coxib useGastroenterology, 2003
- Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patientGastroenterology, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: Retrospective cohort study of an elderly populationArthritis & Rheumatism, 2000
- Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid ArthritisJAMA, 1999
- A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2–specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritisGastroenterology, 1999
- Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. The importance of drug and surgery costsArthritis & Rheumatism, 1997
- Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugsJournal of General Internal Medicine, 1996
- A Chronic Disease Score with Empirically Derived WeightsMedical Care, 1995
- Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humansGastroenterology, 1993